Prime Therapeutics Removes Intelence from Medicare Part D Formularies
The first generic equivalent of the HIV therapeutic is now available.
Prime Therapeutics has removed Janssen’s Intelence (etravirine) from its Medicare Part D formularies effective July 15, 2021. A generic therapy is now available and will be covered instead.
This will impact several Medicare Part D formularies, including Ideal Formularies, Value & Essential Formularies, Client Specific Formularies (Alignment, Asuris, Capital Blue Cross, HCSC, Horizon, Regence).
Intelence has been available since 2008, when the FDA granted accelerated approval for use in combination with antiretroviral (ARV) medications for treatment-experienced adult patients who have evidence of viral replication and HIV-1 strains resistant to an NNRTI and other antiretroviral agents. n November 2009, the FDA granted Intelence traditional FDA approval based on 48-week data from the two studies, DUET 1 and DUET 2.
The FDA also approved Intelence in March 2012 for use in pediatric patients 6 years to 18 years of age.
The FDA approved Amneal Pharmaceutical’s generic in June 2021, and the company has already made the therapy available. Etravirine is the first generic equivalent for Intelence.
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
July 25th 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
FDA Extends Review of Blenrep Combinations in Multiple Myeloma
July 24th 2025Last week, an FDA advisory committee against the risk-benefit profile of Blenrep in combination with other therapies. Regulators and reviewers were concerned about the ocular side effects and dosing and tolerability. The new action date is Oct. 23, 2025.
Read More
Sarepta to Pause Shipments of the Gene Therapy Elevidys
July 22nd 2025Sarepta officials said the temporary halt in shipments was done to maintain a productive working relationship with regulators while they address a safety labeling update about the risk of acute liver disease related to Elevidys.
Read More
